Loading
companiesCompany
ResistanceBio (Viosera Therapeutics)
ResistanceBio set out to design drugs that stop cancers becoming resistant to treatment. The company is no longer active.
Overview
ResistanceBio, incorporated as Viosera Therapeutics, aimed to solve acquired drug resistance in cancer by modelling how tumours evolve under therapy and designing compounds against the resistance routes. It grew to about 15 people with sites in San Francisco and the St. Louis area before the YC directory marked it inactive. Recorded here as wound down; no acquirer or successor is named because none was found in a primary source.
Headquarters
San Francisco, CA, US
Funding
All startupsWound downYC W19
Investors
Type
Stage
Wound down · Y Combinator Winter 2019
Y Combinator profile
Similar pages
- CompanySerinus Biosciences
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.